NWBO has the ability to be vertically integrated by owning a CDMO. Or it could decide to not do that in order to keep those liabilities off their balance sheet. I really don't care.
We have three routes for manufacturing. CRL, Advent, and eventually FlaskWorks. Even if the price falls to 50K USD per patient, that's an insane market cap for the entire oncology space. You can continue looking for a conspiracy. I'll keep buying NWBO.
News 
Market Data 
Discover 
AI
